Literature DB >> 8473771

Haemophilus influenzae type b disease in north-west England.

C Quigley1, E B Kaczmarski, D M Jones, A R Haycox.   

Abstract

A study was made in the north-west of England during 1989 in order to ascertain the incidence of serious Haemophilus influenzae infection, its short-term morbidity and certain characteristics of treatment. The incidence of culture-proven infection was 28 per 100,000 children under 5 years of age. Case fatality was 3%, one of the deaths being in a 6-year-old child. Some of the information obtained will help to assess the cost-effectiveness of the new vaccine to be administered to children in the U.K. The mean length of stay in hospital for all cases was 10 days. Of a total of 87 patients, 20 (23%) were admitted to an intensive therapy unit while five were transferred from a district general hospital to a regional paediatric unit. The estimated average cost per episode of acute care was 2700 pounds. Antibiotic regimens varied considerably.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473771     DOI: 10.1016/0163-4453(93)93112-h

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

1.  Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania.

Authors:  V Luca; B D Gessner; C Luca; T Turcu; S Rugina; C Rugina; M Ilie; E Novakova; C Vlasich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-26       Impact factor: 3.267

2.  Invasive Haemophilus influenzae disease: an ecological study of sociodemographic risk factors before and after the introduction of Hib conjugate vaccine.

Authors:  Babatunde Olowokure; Nicholas J Spencer; Jeremy I Hawker; Iain Blair; Ralph L Smith
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  The cost of hospital care for management of invasive group A streptococcal infections in England.

Authors:  G J Hughes; A J VAN Hoek; S Sriskandan; T L Lamagni
Journal:  Epidemiol Infect       Date:  2014-09-29       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.